Condition
Recurrent Peritoneal Malignant Mesothelioma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
3 shownAtezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsNCT03074513 · 2017-03-03
ACTIVE_NOT_RECRUITINGMethoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or CarboplatinNCT02535312 · 2016-03-08
ACTIVE_NOT_RECRUITINGPembrolizumab in Treating Patients With Malignant MesotheliomaNCT02399371 · 2015-03-31
COMPLETEDCommon interventions
Leading sponsors
Trial status mix
ACTIVE_NOT_RECRUITING2
COMPLETED1
Phase mix
PHASE23
PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.